article thumbnail

Why Dr. Sue Sisley Sued the DEA for Stonewalling Cannabis Research

NORML

We also spoke with her attorneys, who explained why they believed the DEA broke the law by holding up long-promised medical marijuana research licenses. It’s been nearly three years since the DEA announced its revolutionary cultivator program. Dr. Sue Sisley. Later that night, everyone celebrated at a hotel bar.

DEA 227
article thumbnail

New U.S. Research Efforts Could Catalyze Medical Cannabis’ Adoption in the Pharmaceutical Industry

Veriheal

The final goal is to introduce medicinal cannabis products to the pharmaceutical drug market. Drug Enforcement Agency (DEA). This means that the medical and scientific communities can now celebrate broader access to research for the production of pharmaceutical products that are safer than smokable or vaporizable cannabis.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA Approves CBD-Containing Drug - Will the DEA Finally Step Up?

MJ Business Attorneys

Moreover, the ball is in the Drug Enforcement Agency’s (DEA) court. The FDA can make recommendations to the DEA about substances subjected to scheduling under the CSA, but the DEA is the entity with the power to reschedule CBD. In the recent case Hemp Industries Associations v.

DEA 113
article thumbnail

‘The most meaningful cannabis reform in decades’: Experts weigh in on new DEA rules

The Cannigma

All that is about to change, thanks to a change at the DEA , which cultivators and industry experts say will be monumental for cannabis research, medical marijuana patients, and potentially the broader legal status of the plant itself. “We BRC) told The Cannigma this week. Junk’ cannabis ‘ill-suited for clinical trials’. Shutterstock).

DEA 133
article thumbnail

DEA Increases Access to Cannabis for Research Purposes

Veriheal

” The doorways opening to new cannabinoid research are monumental. Over the next decade, the United States could stand to see an explosion in the research of cannabinoid therapies. Another company that will be cultivating cannabis for research is a pharmaceutical research company.

DEA 59
article thumbnail

Royal Emerald Pharmaceuticals Partners with BioHarvest Sciences to Supply Disruptive Cannabis Solutions to Companies Conducting FDA-Approved Medical Research

Cannabis Law Report

This collaboration ensures first-of-their-kind consistent cannabinoid compositions for 575 DEA-licensed cannabis medical research institutions developing cures for PTSD, pain management, anxiety conditions and more Vancouver, British Columbia and Rehovot, Israel–(Newsfile Corp.

article thumbnail

Scientists Think the Synthetic Cannabinoids in Sativex Can Beat Brain Cancer

SpeedWeed

It’s the first cannabis-derived pharmaceutical to be legalized in many countries around the world, including the UK, Spain, United States, Canada, and New Zealand. . “It’s not just street cannabis put into a bottle,” GW Pharmaceutical CEO Justin Gover once told the Guardian. View original article.